ORENCIA® 250 mg is a sterile, preservative-free lyophilized powder supplied in a single-use glass vial, intended to be reconstituted and administered as an intravenous infusion. It contains abatacept, a selective co-stimulation modulator that helps regulate T-cell activation — a core driver of autoimmune inflammation. By interrupting this immune pathway, ORENCIA® reduces joint inflammation, improves mobility, and slows long-term structural damage associated with chronic inflammatory arthritis.

Approved Indications

• Moderate to severe Rheumatoid Arthritis in adults (often following inadequate response to DMARDs)

• Active Psoriatic Arthritis in adults

• Polyarticular Juvenile Idiopathic Arthritis in pediatric patients

Clinical Benefits

• Helps relieve pain, swelling, stiffness and improves function

• May reduce radiographic progression of joint damage

• Appropriate for patients who do not respond well to anti-TNF therapies

• Long-term disease management with monitored safety profile

Administration & Dosage

• For IV use only, prepared by healthcare professionals

• Weight-based dosing, given over infusion intervals (initiation + maintenance schedule)

• Infusions performed in a clinical setting where monitoring is available

Safety & Considerations

• Increased risk of infections — screening recommended prior to treatment

• Infusion-related reactions may occur

• Not recommended with other biologic immunosuppressants

• Live vaccines should be avoided during treatment

• Continuous medical evaluation required for optimal management